MT. KISCO, N.Y., Dec. 07, 2016 -- ImmuDyne, Inc. (OTCQB:IMMD) (“Immudyne” or the “Company”), a leader in the development and marketing of OTC health and wellness products addressing large unmet needs, today announced that a Definitive Agreement has been reached with Dr. Lilliana Ramirez to endorse and assist with the development of a new line of skincare products based on Immudyne’s proprietary Yeast Beta Glucan ingredient. The brand, Inate MD, will be launched nationally January 1, 2017.
Dr. Lilliana Ramirez is a practicing, board certified dermatologist with a distinguished track record in medicine and academics. She graduated Magna Cum Laude from the University of Puerto Rico and has received many awards for both her research and the practice of medicine.
“Immudyne is partnering with and associating our brand with yet another highly accomplished dermatologist,” stated Mark McLaughlin, President and CEO of Immudyne.
“I’m very pleased to be working with Immudyne,” said Dr. Ramirez. "The Inate MD skincare line is backed by excellent science and a great management team. I think my patients and consumers across the county will enjoy and benefit from use of the Inate MD product line.”
The Inate MD line will initially be available exclusively online and will consist of a Serum, Moisturizer, Instant Wrinkle Eraser and an optional nutritional supplement to support healthier skin and the human Immune System.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Reliance should not be placed on forward-looking statements because they involve unknown risks, uncertainties and other factors, which are, in some cases, beyond the control of Immudyne. Actual events, performance or results could differ materially from the anticipated events, performance or results expressed or implied by such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
About ImmuDyne, Inc.
lmmuDyne, Inc. (the "Company") is a health and wellness company which develops, manufactures, markets, and sells innovative lifestyle products. The Company's lead products contain its proprietary yeast beta glucans that have been shown through testing and analysis to support the immune system. ImmuDyne also has a majority owned direct marketing division that markets immune support, skincare and hair loss products directly to consumers around the world. All of the Company’s intellectual property is protected by patents and/or trade secrets. Additional information can be found on the web at www.immudyne.com.
Contact: lmmuDyne, Inc. Mark McLaughlin: +1-914-714-8901


Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 



